Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$30.56 – $37.33
85% from low
Exchange
ARCX
ETF
Borrow rate
9.89%
Hard to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| GDOCGoldman Sachs Future Health Care Equity ETF | $36.29 | +0.00% | $20M | — |
| BYREPrincipal Real Estate Active Opportunities ETF | $27.50 | -0.67% | $25M | — |
| CAFGPacer US Small Cap Cash Cows Growth Leaders ETF | $34.06 | +0.78% | $25M | — |
| MAYTAIM ETF Products Trust - AllianzIM U.S. Large Cap Buffer10 May ETF | $36.81 | +0.32% | $19M | — |
| MEDIHarbor Health Care ETF (MEDI) |
No company description on file.
No one on the platform currently holds GDOC.
No tracked institution reports a position in GDOC as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-23 | $0.1133 | 2025-12-30 |
| 2024-12-23 | $0.0058 | 2024-12-30 |
| 2023-12-26 | $0.1789 | 2024-01-02 |
No one on the platform has traded GDOC yet.
| $33.95 |
| +0.37% |
| $23M |
| — |
| NOVZTrueShares Structured Outcome (November) ETF | $47.05 | +0.56% | $20M | — |
| STXIStrive International Developed Markets ETF | $31.10 | +0.00% | $24M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$GDOC Golden Doc microcap with limited visibility. Fundamentals are unclear. Liquidity risk remains high.
View on StockTwits ↗$GDOC - Goldman Sachs pin risk is increasing. Hedging Goldman Calls is getting hard https://www.macroaxis.com/stock-options/GDOC/Goldman-Sachs-ETF?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$ARKG $GDOC $IBB $SPY $XBI this was the last time I posted about buying Xbi and it did great , but slow though in my opinion it could retest 70,good time to start with Xbi
View on StockTwits ↗$GDOC - Goldman Sachs implied volatility is increasing. https://www.macroaxis.com/stock-options/GDOC/Goldman-Sachs-ETF?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$GDOC - Risk alert: Goldman Sachs maximum pain price is depinning https://www.macroaxis.com/stock-options/GDOC/Goldman-Sachs-ETF?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$GDOC - Pin risk dips as more Goldman Sachs call traders are getting in https://www.macroaxis.com/stock-options/GDOC/Goldman-Sachs-ETF?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$GDOC - Risk alert: Goldman Sachs max pain price is slipping https://www.macroaxis.com/stock-options/GDOC/Goldman-Sachs-Future?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗@profitaker0 And promoting gene editing/CRSPR. $GDOC is down 20% since inception, and $ARKK down over 60%. I like CRSP, NTLA, & BEAM, but liked BLUE first.
View on StockTwits ↗$XBI biotech is the opposite of what everyone is talking about on tv Not stable, not profitable , valued on expectation of future profits What I can tell you is if you look at long term compare charts xbi always beats the $SPY by a lot! 174 to to 70 Xbi has had many big draw downs in past , I been following this one for a decade plus I will not post pre fda biotech stocks, I never post penny stocks What I will say is xbi is a really good aggressive etf for access to biotech and if u buy now and add a little if it goes lower, it will beat snp over next 5 years for sure imo , by a lot I can't believe xbi is down here , you can also look at $IBB $GDOC or $ARKG but I like xbi for it's equal weight access to the smaller innovative US biotech industry which has always done well. Also cheaper then the active options and much safer then individual biotech stocks This is the time especially on down days to buy xbi
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.